In-depth analysis: Price and cost of crizotinib targeted drugs

Crizotinib, as a highly effective treatment for cancers with specific genetic mutations, is widely used in the treatment of non-small cell lung cancer (NSCLC), anaplastic large cell lymphoma (ALCL), and anaplastic lymphoma kinase (ALK)-positive inflammatory myofibroblastic tumor (IMT). As a tyrosine kinase inhibitor, crizotinib effectively inhibits the growth and spread of cancer cells by precisely acting on specific areas in cancer cells.

However, this highly effective treatment drug is not easy to obtain, and its price is relatively high, which has become the focus of many patients and family members. In the domestic market, the original drug of crizotinib capsules (XALKORI/XALKORI) is relatively expensive, and the price of each box of products of different specifications may exceed RMB 10,000. This undoubtedly brings huge financial pressure to many patients' families with limited financial conditions. For patients who meet the indications, the national medical insurance policy provides a certain reimbursement ratio, which reduces the patient's financial burden to a certain extent. But even so, the out-of-pocket expense is still a big expense.

The price of the original crizotinib drug in overseas markets is also high. However, it is worth mentioning that there are also some relatively affordable generic crizotinib drugs on the overseas market. These generic drugs are basically similar in ingredients to the brand-name drugs, but their prices are quite different. For example, generic drugs produced by pharmaceutical companies in countries such as Bangladesh and Laos cost about 2,000 yuan per box, which undoubtedly provides new possibilities for patients seeking more affordable treatment options. Patients and their families also need to be cautious when choosing overseas drugs to ensure the quality of the drugs and the reliability of their sources.